[Haemophilus influenzae ORL and bronchopulmonary infections: role of pristinamycin].
Dabernat
H
H
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D006192:Haemophilus Infections / Q000188:drug therapy* / Q000453:epidemiology; D006193:Haemophilus influenzae; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D014769:Virginiamycin / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D014769:Virginiamycin
Les infections ORL et broncho-pulmonaires, à Haemophilus influenzae: place de la pristinamycine.